List of Excipients in Branded Drug DISULFIRAM

Generic Drugs Containing DISULFIRAM

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	disulfiram	0054-0356	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	disulfiram	0054-0356	MAGNESIUM STEARATE
Hikma Pharmaceuticals USA Inc	disulfiram	0054-0356	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in DISULFIRAM?

# Of NDCs	Excipient
5	ANHYDROUS LACTOSE
9	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM

Disulfiram Excipient Strategy and Commercial Opportunities

Last updated: August 11, 2026

Disulfiram is an established, low-cost small-molecule treatment for alcohol use disorder with limited branded revenue and no biosimilar exposure. Its commercial potential is concentrated in differentiated oral delivery, adherence products, repurposing formulations, and geographic markets where alcohol-use-disorder treatment remains underpenetrated. The strongest formulation opportunities address poor aqueous solubility, variable exposure, moisture sensitivity, gastrointestinal tolerability, and long-term adherence.

What is the FDA status of disulfiram?

Disulfiram is FDA-approved for the adjunctive treatment of selected patients with chronic alcoholism who can abstain from alcohol and understand the risks of the disulfiram-alcohol reaction. It is not an aversion therapy that removes alcohol craving, and it has no FDA approval for oncology, viral disease, or other repurposing indications.

Regulatory attribute	Disulfiram status
Active ingredient	Disulfiram
Primary indication	Alcohol use disorder, as an adjunct to psychosocial treatment
Dosage forms	Immediate-release oral tablets, generally 250 mg and 500 mg
FDA pathway	Legacy 505(b)(2) or ANDA opportunities depend on product design
Biosimilar pathway	Not applicable; disulfiram is a small molecule
Reference product	Antabuse was the historical branded product; generic products dominate
FDA exclusivity	No meaningful current new-drug exclusivity associated with the legacy product
Orange Book exposure	Legacy product and generic listing status must be verified against the current FDA Orange Book and Drugs@FDA databases
Current commercial model	Generic, low-price oral therapy
Approved repurposing indications	None

FDA labeling requires patients to avoid alcohol, including alcohol in beverages, medicines, sauces, toiletries, and other products. The reaction can occur for up to 14 days after discontinuation, which makes patient counseling and adherence controls central product attributes (DailyMed, 2024).

What excipient problems must a disulfiram formulation solve?

The main formulation constraints are low water solubility, variable oral absorption, chemical sensitivity, and the need to avoid unnecessary alcohol exposure.

Solubility and dissolution

Disulfiram is practically insoluble in water. A conventional compressed tablet can therefore show dissolution-dependent absorption, particularly when manufacturing variables alter particle size, wetting, granulation, or compression force.

The preferred first-generation strategy is a robust immediate-release tablet using:

• A directly compressible diluent such as microcrystalline cellulose, mannitol, or dibasic calcium phosphate.
• A superdisintegrant such as crospovidone, croscarmellose sodium, or sodium starch glycolate.
• A wetting agent such as sodium lauryl sulfate or poloxamer, used at the lowest level that improves dissolution without creating tolerability or stability problems.
• A glidant, typically colloidal silicon dioxide, to control flow.
• A lubricant, usually magnesium stearate, with controlled mixing time to prevent hydrophobic over-lubrication.
• A film coat that limits moisture uptake without materially slowing tablet disintegration.

A formulation developer should establish a dissolution target that is more discriminating than a single endpoint. Profiles across pH 1.2, pH 4.5, and pH 6.8 media can identify whether the product is sensitive to gastric pH, surfactant concentration, or particle-size distribution.

Moisture, light, and packaging

Disulfiram contains sulfur-rich functional groups and should be managed as a moisture- and oxidation-sensitive active until stability data support a less restrictive position. The commercial package should favor:

• High-barrier blister packaging, particularly aluminum-aluminum blisters.
• HDPE bottles with an induction seal and desiccant where unit-dose packaging is not economical.
• Low-moisture excipient grades.
• Minimal aqueous processing.
• Controlled exposure to heat, light, and oxygen during manufacture.
• Stability testing that includes assay, related substances, dissolution, water activity, and tablet mechanical properties.

A low-cost tablet with an expensive moisture-protective package may lose its margin advantage. Packaging selection should therefore be linked to the product's intended market. Unit-dose blisters are more attractive for supervised treatment, correctional-health programs, and adherence programs. Bottles are generally more competitive in retail generic channels.

Alcohol-containing excipients and patient safety

A disulfiram product should avoid ethanol-containing liquid vehicles and should carefully assess excipients that may create confusion about alcohol exposure. This issue is more important for oral liquids, orally disintegrating products, sprays, and compounded preparations than for standard tablets.

The product label should clearly address:

• Ethanol in liquid medicines.
• Alcohol-containing flavor systems.
• Propylene glycol and other solvent systems when used in liquid formulations.
• Topical products and mouthwashes.
• The prolonged duration of the disulfiram-alcohol interaction after treatment stops.

A liquid product may improve dosing flexibility but creates greater excipient and labeling risk than a tablet.

Which excipient platforms have the strongest commercial potential?

Immediate-release tablet

The immediate-release tablet is the lowest-risk platform. It can compete through improved dissolution, smaller tablet size, lower tablet weight, better taste masking, or packaging designed for adherence.

The commercial limitation is price. Generic tablets already meet the basic clinical need, so an improved tablet requires a measurable advantage such as:

• Once-daily dose administration.
• Lower pill burden.
• Reduced tablet friability.
• Better dissolution consistency.
• Calendar blister packaging.
• Dispensing controls for supervised therapy.
• Improved stability in hot and humid climates.

A standard 250 mg or 500 mg tablet with conventional excipients is unlikely to support strong patent protection unless the claims establish a specific composition, dissolution profile, impurity limit, or manufacturing process.

Orally disintegrating tablet

An orally disintegrating tablet could support administration in supervised settings and reduce swallowing barriers. The formulation would require careful control of:

• Taste masking.
• Tablet strength.
• Moisture uptake.
• Rapid disintegration.
• Residual solvents.
• Excipient compatibility.

A taste-masked product may use ion-exchange resins, polymeric coating, or lipid-based masking. The principal commercial question is whether the product improves observed adherence enough to justify a premium over a conventional tablet.

Oral granules or sprinkle formulation

Granules could support patients who have difficulty swallowing tablets and may be suitable for controlled dispensing. The formulation must avoid inadvertent alcohol exposure and should be assessed for:

• Uniformity of low-dose administration.
• Stability after opening.
• Compatibility with soft foods.
• Dose loss during transfer.
• Taste and odor control.
• Moisture protection.

This platform is more commercially defensible in pediatric, geriatric, institutional, or specialty-care channels, although disulfiram's safety profile limits pediatric positioning.

Extended-release oral product

An extended-release formulation could reduce peak-to-trough variation and potentially support adherence. It also creates a more complex regulatory and clinical program. The developer would need to characterize:

• Absorption and exposure relative to immediate-release disulfiram.
• Metabolite exposure, especially diethyldithiocarbamate-related species.
• Dose dumping risk.
• Food effects.
• Alcohol-interaction duration.
• Whether altered release changes the severity or timing of the disulfiram-alcohol reaction.

Extended release is a higher-value but higher-risk strategy. It is more suitable for a 505(b)(2) development program than for a conventional ANDA unless the product is therapeutically equivalent under the applicable FDA standards.

Amorphous solid dispersion, lipid system, or nanocarrier

Solubility-enhancing technologies may improve dissolution, but their value depends on whether they produce a clinically relevant pharmacokinetic benefit. Candidate platforms include:

• Amorphous solid dispersions.
• Self-emulsifying drug-delivery systems.
• Lipid nanoparticles.
• Cyclodextrin complexes.
• Polymer-based nanocarriers.
• Micronized or nanomilled disulfiram.

These approaches may be more relevant to repurposing programs than to the low-price alcohol-use-disorder market. A formulation that materially improves systemic exposure could also increase safety, metabolite, and interaction concerns. The development program should not rely on dissolution improvement alone; it should link the formulation to a clinically meaningful exposure or adherence endpoint.

What formulation patents could protect disulfiram products?

The original active-ingredient protection for disulfiram is long expired. Commercial protection must therefore come from secondary patent categories.

Patent category	Potential claim scope	Commercial value
Composition of matter	New disulfiram molecule	Not available for the legacy active
Tablet composition	Excipient ratios, particle size, dissolution, impurity control	Moderate if technically narrow and reproducible
Orally disintegrating formulation	Taste masking, fast disintegration, moisture protection	Moderate
Extended release	Matrix, coating, multiparticulate release system	Potentially high
Nanoparticle or dispersion	Particle engineering, carrier system, improved exposure	Potentially high but validation-intensive
Combination product	Disulfiram with copper or another active	Potentially high, with interaction and regulatory risks
Method of use	Oncology, infectious disease, neuropsychiatric or other repurposed use	Dependent on clinical evidence and enforceability
Manufacturing process	Low-temperature processing, impurity reduction, continuous manufacturing	Usually moderate
Packaging	Moisture-control configuration or adherence package	Generally weak unless linked to product performance
Diagnostic or adherence system	Supervised dosing, digital confirmation, alcohol monitoring	Could create system-level differentiation

The most defensible formulation claims would tie composition to measurable performance, such as dissolution, stability, impurity profile, or pharmacokinetic behavior. Broad claims covering "disulfiram with a solubilizer" are vulnerable to prior-art attacks and design-around strategies.

What patents protect disulfiram repurposing programs?

Repurposing patents may cover treatment of cancer, viral infection, inflammation, or neurodegenerative disease. These programs have attracted academic and biotechnology interest because disulfiram can interact with copper-dependent pathways, proteasomal processes, aldehyde dehydrogenase biology, and other cellular mechanisms. The evidence remains indication-specific, and preclinical activity does not establish an approved clinical use.

A repurposing patent portfolio is stronger when it includes:

1. A defined patient population or biomarker.
2. A specific dose and schedule.
3. A validated combination partner.
4. A pharmaceutical composition with reproducible exposure.
5. Clinical data supporting the claimed mechanism.
6. Continuation or divisional filings directed to distinct treatment populations.

When does disulfiram lose exclusivity?

Disulfiram's core exclusivity has already expired. The commercial market is therefore governed by generic competition, manufacturing economics, regulatory compliance, and any surviving secondary patents.

Exclusivity type	Current commercial relevance
Original molecule patent	Expired
Legacy Antabuse exclusivity	Expired
New chemical entity exclusivity	Not relevant to current generic products
Pediatric exclusivity	No material current protection identified
Orphan exclusivity	No approved orphan indication for disulfiram
Regulatory data exclusivity	Not a meaningful barrier for the legacy product
Formulation patents	Product-specific; must be assessed claim by claim
Method-of-use patents	Potentially relevant to repurposed indications
Trade secrets	Relevant to process control, impurity reduction, and manufacturing economics

No biosimilar entry risk exists because disulfiram is not a biologic. The relevant threat is generic substitution and the possible launch of differentiated 505(b)(2) products.

Are there Paragraph IV challenges or active disulfiram litigation?

No major current Paragraph IV challenge or high-value patent dispute is identified in the public regulatory and patent materials cited here for legacy disulfiram tablets. That outcome is commercially predictable because the basic product is old, generic, and weakly protected by exclusivity.

A new formulation could create Paragraph IV risk if it relies on listed patents covering:

• A specific extended-release system.
• A proprietary particle-size distribution.
• A combination with copper or another agent.
• A method of treating a newly approved indication.
• A device or adherence system listed in the Orange Book.

For an entrant, the main legal risks are likely to be patent validity, claim construction, obviousness, written description, and infringement by an excipient or release-system design. For a sponsor, the best litigation position would come from claims tied to clinical performance rather than routine tablet manufacturing.

Which companies are challenging disulfiram exclusivity?

The market is supplied primarily through generic manufacturers and distributors rather than through a concentrated branded challenger group. Company-specific ANDA ownership and current marketing status should be checked in FDA databases because supply arrangements change through acquisitions, discontinuations, and private-label agreements.

The competitive structure has four tiers:

1. Generic tablet manufacturers competing on cost and supply reliability.
2. Contract development and manufacturing organizations offering formulation or packaging upgrades.
3. Specialty pharmaceutical companies developing adherence-oriented products.
4. Biotechnology companies evaluating disulfiram in repurposed indications.

The fourth tier is more relevant to licensing and venture investment than to the existing alcohol-use-disorder tablet market.

How does disulfiram compare with competing alcohol-use-disorder medicines?

Attribute	Disulfiram	Naltrexone	Acamprosate
Primary mechanism	Alcohol-metabolism blockade through aldehyde dehydrogenase inhibition	Opioid receptor antagonism	Glutamatergic and GABAergic modulation
Adherence dependence	High	Moderate for oral dosing; lower for injectable product	High because of multiple daily doses
Generic competition	Strong	Strong	Strong
Long-acting option	Not established as an FDA-approved product	Injectable option exists	No long-acting approved option
Main formulation opportunity	Adherence, dissolution, modified release	Long-acting delivery and tolerability	Reduced pill burden and modified release
Key safety constraint	Severe alcohol-disulfiram reaction	Hepatic and opioid-related considerations	Renal restrictions and pill burden
Biosimilar risk	None	None	None

Disulfiram's disadvantage is that it works best when the patient is motivated and treatment is supervised. Its advantage is that the pharmacologic consequence of alcohol consumption is clear and potentially useful in structured programs. A new product must improve adherence or administration rather than merely reproduce the existing tablet.

What licensing deals could create commercial value?

The most credible licensing opportunities are not based on generic disulfiram supply. They involve platform technology or a new indication.

Formulation licensing

A formulation company could license:

• A stable amorphous dispersion.
• A long-acting oral or implantable system.
• An orally disintegrating product.
• A moisture-resistant tablet and blister package.
• A taste-masking platform.
• A supervised-dosing system.

The licensor should seek claims that cover both the composition and its therapeutic use. A formulation patent with no demonstrable clinical advantage will have limited negotiating value.

Repurposing licensing

A biotechnology company could license disulfiram for oncology or another investigational indication. The transaction would normally depend on:

• Preclinical reproducibility.
• Biomarker selection.
• Combination-treatment rationale.
• Clinically achievable exposure.
• Freedom to operate around formulation and method-of-use patents.
• A clear FDA development pathway.

The legacy generic product lowers active-ingredient cost but does not eliminate the need for clinical, manufacturing, and regulatory investment.

Geographic licensing

Potentially attractive regions include markets where:

• Alcohol-use-disorder treatment is underdiagnosed.
• Supervised treatment is common.
• Imported generic supply is inconsistent.
• Heat and humidity make conventional packaging unreliable.
• Local manufacturing or government procurement provides volume.

The strongest geographic strategy may combine low-cost tablets with high-barrier blister packaging and institutional distribution rather than premium retail pricing.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are manageable but commercially relevant. The key controls are:

• Active-ingredient particle size.
• Blend uniformity.
• Lubrication time.
• Tablet hardness and disintegration.
• Dissolution reproducibility.
• Related substances.
• Moisture exposure.
• Packaging seal integrity.
• Supplier qualification for the active and functional excipients.

The most practical process patents would claim a narrow set of operating conditions that reduce impurities or improve dissolution without requiring expensive equipment. A continuous manufacturing process could create cost and quality advantages, but the patent value would depend on whether competitors can reproduce the result through conventional batch processing.

What is the revenue exposure and commercial opportunity?

Legacy disulfiram tablets have limited revenue exposure because they are inexpensive, generic, and clinically substitutable. A sponsor should not underwrite a branded-product strategy based on market share alone.

The better commercial opportunities are:

Opportunity	Revenue logic	Main risk
Premium adherence tablet	Higher price for supervised care and improved administration	Limited willingness to pay
ODT or sprinkle formulation	Access to swallowing-challenged patients and institutions	Taste and stability
Extended release	Lower dosing frequency and potential adherence benefit	Clinical and regulatory complexity
Combination product	Differentiated repurposing or enhanced mechanism	Drug-interaction and patent risk
Oncology formulation	Higher value per patient if efficacy is proven	Clinical failure and crowded IP
Emerging-market package	Institutional volume and improved stability	Procurement pricing pressure
CDMO or platform licensing	Milestone and royalty revenue	Dependence on partner development

A commercial model should separate the low-margin alcohol-use-disorder market from the higher-risk, higher-value repurposing market. The two markets require different formulation, evidence, pricing, and patent strategies.

Key Takeaways

• Disulfiram's original exclusivity has expired, and generic tablets dominate.
• The strongest excipient priorities are dissolution enhancement, moisture control, process robustness, and avoidance of alcohol-containing liquid systems.
• Immediate-release tablets are the lowest-risk products but have limited pricing power.
• Orally disintegrating, sprinkle, extended-release, and solubility-enhanced products offer greater differentiation.
• Secondary patents should focus on measurable formulation performance, not broad excipient combinations.
• No biosimilar risk applies because disulfiram is a small molecule.
• No major current Paragraph IV or legacy-product patent dispute is identified in the cited public materials.
• Repurposing opportunities may offer higher commercial value but require clinical proof, indication-specific patents, and a clear regulatory strategy.
• Packaging and supervised administration can create more practical commercial value than a conventional excipient substitution.
• Generic supply, institutional procurement, and geographic packaging requirements are central to near-term commercial planning.

FAQs

Can disulfiram be developed as an oral liquid?

Yes, but an oral liquid creates greater risk from ethanol-containing vehicles, flavor systems, preservative compatibility, dose uniformity, and patient counseling. A nonalcoholic liquid would require strong stability and taste-masking data.

Is a disulfiram-copper product commercially attractive?

Potentially, particularly for investigational oncology programs. The product would need a defined dose relationship, clinical rationale, interaction assessment, and patent claims that distinguish the combination from routine co-administration of generic products.

Can excipients change the duration of the disulfiram-alcohol reaction?

They may alter disulfiram exposure and metabolite kinetics, but a modified-release product cannot assume an equivalent safety profile. Duration and severity of the alcohol interaction would require dedicated pharmacokinetic and clinical evaluation.

Is disulfiram suitable for a 505(b)(2) application?

A 505(b)(2) pathway may be relevant for a materially modified formulation, dosage form, route, or indication. The regulatory burden depends on the extent of reliance on FDA findings for the existing product and the new clinical evidence required.

What is the most defensible near-term product concept?

A moisture-protected, adherence-oriented 250 mg or 500 mg tablet with demonstrably improved dissolution, calendar blister packaging, and a clear supervised-treatment use case is the most practical near-term concept. Extended-release and repurposed products offer greater upside but carry substantially higher development risk.

References

1. DailyMed. (2024). Disulfiram tablet prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/

4. National Center for Biotechnology Information. (2024). Disulfiram. PubChem Compound Summary. https://pubchem.ncbi.nlm.nih.gov/compound/Disulfiram

5. National Institute of Diabetes and Digestive and Kidney Diseases. (2019). Disulfiram. In LiverTox: Clinical and research information on drug-induced liver injury. National Institutes of Health. https://www.ncbi.nlm.nih.gov/books/NBK548053/

6. Skinner, M. D., Lahmek, P., Pham, H., Aubin, H. J., & Berlin, I. (2014). Disulfiram efficacy in the treatment of alcohol dependence: A meta-analysis. PLoS ONE, 9(2), e87366. https://doi.org/10.1371/journal.pone.0087366

7. European Medicines Agency. (2023). Guideline on the investigation of bioequivalence. https://www.ema.europa.eu/

8. U.S. Food and Drug Administration. (2019). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Guidance for Industry. https://www.fda.gov/###